Compounds > ruboxistaurin
Page last updated: 2024-09-04

ruboxistaurin and erlotinib

ruboxistaurin has been researched along with erlotinib in 6 studies

Compound Research Comparison

Studies
(ruboxistaurin)		Trials
(ruboxistaurin)		Recent Studies (post-2010)
(ruboxistaurin)		Studies
(erlotinib)		Trials
(erlotinib)		Recent Studies (post-2010) (erlotinib)
20329562210180

Protein Interaction Comparison

ProteinTaxonomyruboxistaurin (IC50)erlotinib (IC50)
epidermal growth factor receptor isoform a precursorHomo sapiens (human)0.001
Cyclin-G-associated kinaseHomo sapiens (human)0.474
Tyrosine-protein kinase JAK2Homo sapiens (human)4
Solute carrier organic anion transporter family member 2B1 Homo sapiens (human)0.55
Bile salt export pumpHomo sapiens (human)10
Proto-oncogene tyrosine-protein kinase SrcGallus gallus (chicken)0.99
Epidermal growth factor receptorHomo sapiens (human)0.5294
Receptor tyrosine-protein kinase erbB-2Homo sapiens (human)0.7171
Cytochrome P450 3A4Homo sapiens (human)0.016
Platelet-derived growth factor receptor betaHomo sapiens (human)0.0122
Serine/threonine-protein kinase B-rafHomo sapiens (human)0.06
Corticosteroid 11-beta-dehydrogenase isozyme 1 Rattus norvegicus (Norway rat)0.03
Platelet-derived growth factor receptor alphaHomo sapiens (human)8.12
Vascular endothelial growth factor receptor 1 Homo sapiens (human)0.25
Receptor tyrosine-protein kinase erbB-3Homo sapiens (human)0.2586
Sodium-dependent dopamine transporterRattus norvegicus (Norway rat)0.369
Cyclin-dependent kinase 2Homo sapiens (human)1.14
Adenosine receptor A1Rattus norvegicus (Norway rat)0.0063
Serine/threonine-protein kinase B-raf Mus musculus (house mouse)0.06
Cytochrome P450 2C19Homo sapiens (human)0.087
Vascular endothelial growth factor receptor 3Homo sapiens (human)0.25
Vascular endothelial growth factor receptor 2Homo sapiens (human)0.8349
D(1A) dopamine receptorSus scrofa (pig)0.3
Fatty-acid amide hydrolase 1Rattus norvegicus (Norway rat)0.0095
Synaptic vesicular amine transporterRattus norvegicus (Norway rat)0.001
Focal adhesion kinase 1Homo sapiens (human)7.4
Receptor tyrosine-protein kinase erbB-4Homo sapiens (human)0.6925
Canalicular multispecific organic anion transporter 1Homo sapiens (human)10
Alpha-1A adrenergic receptor Sus scrofa (pig)0.3
Serine/threonine-protein kinase TBK1Homo sapiens (human)2.2
Broad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)0.13

Research

Studies (6)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's3 (50.00)29.6817
2010's3 (50.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Atteridge, CE; Azimioara, MD; Benedetti, MG; Biggs, WH; Carter, TA; Ciceri, P; Edeen, PT; Fabian, MA; Floyd, M; Ford, JM; Galvin, M; Gerlach, JL; Grotzfeld, RM; Herrgard, S; Insko, DE; Insko, MA; Lai, AG; Lélias, JM; Lockhart, DJ; Mehta, SA; Milanov, ZV; Patel, HK; Treiber, DK; Velasco, AM; Wodicka, LM; Zarrinkar, PP1
Bullock, AN; Fedorov, O; Knapp, S; Marsden, B; Müller, S; Pogacic, V; Rellos, P; Schwaller, J; Sundström, M1
Atteridge, CE; Campbell, BT; Chan, KW; Ciceri, P; Davis, MI; Edeen, PT; Faraoni, R; Floyd, M; Gallant, P; Herrgard, S; Hunt, JP; Karaman, MW; Lockhart, DJ; Milanov, ZV; Morrison, MJ; Pallares, G; Patel, HK; Pritchard, S; Treiber, DK; Wodicka, LM; Zarrinkar, PP1
Russu, WA; Shallal, HM1
Ciceri, P; Davis, MI; Herrgard, S; Hocker, M; Hunt, JP; Pallares, G; Treiber, DK; Wodicka, LM; Zarrinkar, PP1
Aiche, S; Bassermann, F; Becker, W; Canevari, G; Casale, E; Depaolini, SR; Ehrlich, HC; Felder, ER; Feuchtinger, A; Garz, AK; Gohlke, BO; Götze, K; Greif, PA; Hahne, H; Heinzlmeir, S; Helm, D; Huenges, J; Jeremias, I; Kayser, G; Klaeger, S; Koch, H; Koenig, PA; Kramer, K; Kuster, B; Médard, G; Meng, C; Petzoldt, S; Polzer, H; Preissner, R; Qiao, H; Reinecke, M; Reiter, K; Rueckert, L; Ruland, J; Ruprecht, B; Schlegl, J; Schmidt, T; Schneider, S; Schoof, M; Spiekermann, K; Tõnisson, N; Vick, B; Vooder, T; Walch, A; Wilhelm, M; Wu, Z; Zecha, J; Zolg, DP1

Other Studies

6 other study(ies) available for ruboxistaurin and erlotinib

ArticleYear
A small molecule-kinase interaction map for clinical kinase inhibitors.
    Nature biotechnology, 2005, Volume: 23, Issue:3

    Topics: Benzamides; Drug Design; Escherichia coli; Escherichia coli Proteins; Imatinib Mesylate; Microchemistry; Pharmaceutical Preparations; Piperazines; Protein Binding; Protein Interaction Mapping; Protein Kinase Inhibitors; Pyrimidines

2005
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
    Proceedings of the National Academy of Sciences of the United States of America, 2007, Dec-18, Volume: 104, Issue:51

    Topics: Amino Acid Sequence; Binding Sites; Clinical Trials as Topic; Drug Evaluation, Preclinical; Enzyme Stability; Humans; Molecular Sequence Data; Phylogeny; Protein Array Analysis; Protein Conformation; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases

2007
A quantitative analysis of kinase inhibitor selectivity.
    Nature biotechnology, 2008, Volume: 26, Issue:1

    Topics: Binding Sites; Enzyme Activation; Humans; Phosphotransferases; Protein Binding; Protein Interaction Mapping; Protein Kinase Inhibitors; Proteome; Quantitative Structure-Activity Relationship

2008
Discovery, synthesis, and investigation of the antitumor activity of novel piperazinylpyrimidine derivatives.
    European journal of medicinal chemistry, 2011, Volume: 46, Issue:6

    Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Drug Discovery; Drug Screening Assays, Antitumor; Humans; Models, Molecular; Molecular Structure; Piperazines; Protein Kinase Inhibitors; Protein Kinases; Pyrimidines; Stereoisomerism; Structure-Activity Relationship

2011
Comprehensive analysis of kinase inhibitor selectivity.
    Nature biotechnology, 2011, Oct-30, Volume: 29, Issue:11

    Topics: Catalysis; Drug Design; Enzyme Stability; High-Throughput Screening Assays; Humans; Protein Binding; Protein Kinase Inhibitors; Protein Kinases; Proteomics; Signal Transduction; Substrate Specificity

2011
The target landscape of clinical kinase drugs.
    Science (New York, N.Y.), 2017, 12-01, Volume: 358, Issue:6367

    Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cytokines; Drug Discovery; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Lung Neoplasms; Mice; Molecular Targeted Therapy; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Proteomics; Xenograft Model Antitumor Assays

2017